OSE Immunotherapeutics (STU:6OP) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6OP OSE Immunotherapeutics SA STU:6OP
48 GF Score
Price €2.59
GF Value €1.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


OSE Immunotherapeutics  (STU:6OP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


OSE Immunotherapeutics Cyclically Adjusted PS Ratio Related Terms


OSE Immunotherapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Cyclically Adjusted PS Ratio Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.14 6.11 4.54 5.81 4.45

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.56 4.33 5.83 4.24 4.47

STU:6OP vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, OSE Immunotherapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OSE Immunotherapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's Cyclically Adjusted PS Ratio falls into.


STU:6OP
48GF Score
OSE Immunotherapeutics SA STU:6OP
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

OSE Immunotherapeutics's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, OSE Immunotherapeutics's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0.118/120.8900*120.8900
=0.118

Current CPI (Dec25) = 120.8900.

OSE Immunotherapeutics Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.028 100.650 0.034
201712 0.465 101.850 0.552
201812 1.576 103.470 1.841
201912 1.743 104.980 2.007
202012 0.670 104.960 0.772
202112 1.449 107.850 1.624
202212 0.992 114.160 1.050
202312 0.114 118.390 0.116
202412 3.204 119.950 3.229
202512 0.118 120.890 0.118

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is OSE Immunotherapeutics (STU:6OP) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of €2.59 is trading 87.8% above its estimated GF Value™ of €1.38. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for STU:6OP:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €1.38 vs. price of €2.59 (87.8% above fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the STU:6OP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OSE Immunotherapeutics Business Description

Other Exchanges ORPOF:USA0RAD:UKOSE:France
Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
48GF Score

Get the complete analysis for STU:6OP

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.59
Price
€1.38
GF Value